zurück

Albutrepenonacog alfa (re-assessment, 50 M € limit exceeded: hemophilia B; congenital factor IX deficiency)

Subject:

  • Active Substance: Albutrepenonacog alfa
  • Name: Idelvion®
  • Therapeutic area: Hemophilia B
  • Pharmaceutical company: CSL Behring GmbH

Time table:

  • Start: 15.10.2021
  • Final decision by G-BA: 07.04.2022

Final decision:

  • No additional benefit proved